(Circulation. 2000;101:1083.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
Low Molecular Weight Heparin After Mechanical Heart Valve Replacement
Presented in part at the 21st Congress of the European Society of Cardiology, Barcelona, August 1999, and published in abstract form (Eur Heart J. 1999;20:561).
From the Departments of Cardiology (G.M., J.P.C., D.T.), Pharmacy (V.P., A.B.), and Cardiothoracic Surgery (P.L., I.G.), Pitié-Salpétrière Hospital, Paris.
Correspondence to Gilles Montalescot, MD, PhD, Department of Cardiology, Centre Hospitalier Universitaire Pitié-Salpétrière, 47 boulevard de l’Hôpital, 75013, Paris, France. E-mail gilles.montalescot{at}psl.ap-hop-paris.fr
Background—Patients with mechanical heart valves require life-long anticoagulation. We report here the first large and comparative series of consecutive patients anticoagulated with low molecular weight heparin (LMWH) after mechanical heart valve replacement.
Methods and Results—In this comparative, nonrandomized study, 208 consecutive patients who underwent a single or double heart valve replacement with mechanical prostheses were anticoagulated subcutaneously with unfractionated heparin (UH) in the first period (n=106) and LMWH in the second phase (n=102) of the study. Baseline characteristics were similar in the 2 groups. The mean durations of UH and LMWH treatments were 13.6±0.5 and 14.1±0.6 days, respectively (not significant). On the second day of treatment, 87% of patients treated with LMWH had an anti-Xa activity within the range of efficacy (0.5 to 1 IU/mL), but only 9% of UH-treated patients had an activated partial-thromboplastin time value within the therapeutic range (1.5 to 2.5 times control, P<0.0001 between the 2 groups). On the last day of prescription, all LMWH-treated patients had anti-Xa activity above 0.5 IU/mL, but 19% were above 1 IU/mL. In the UH group, 27% of patients had an activated partial-thromboplastin time above 1.5 times control, but 62% were overanticoagulated. Two major bleedings occurred in each group, and one stroke occurred in the UH group.
Conclusions—In this first comparative study, anticoagulation with LMWHs after mechanical heart valve replacement appears feasible, provides adequate biological anticoagulation, and compares favorably with UH anticoagulation. Randomized studies are now needed to further evaluate this new therapeutic approach.
Key Words: heparin • prosthesis • valves
This article has been cited by other articles:
 |
|
 |
|
  D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Rivas-Gandara, I Ferreira-Gonzalez, P Tornos, A Torrents, G Permanyer-Miralda, I Nicolau, E Arellano-Rodrigo, N Vallejo, A Igual, and J Soler-Soler Enoxaparin as bridging anticoagulant treatment in cardiac surgery Heart, February 1, 2008; 94(2): 205 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Spyropoulos Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 63 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 R. W. Emery, A. M. Emery, A. Knutsen, and G. V. Raikar Aortic Valve Replacement with a Mechanical Cardiac Valve Prosthesis Card. Surg. Adult, January 1, 2008; 3(2008): 841 - 856. [Full Text]
|
|
|
|
 |
|
 L. Ozdemir, E. Yeter, E. Bozkurt, and T. Delibasi Hemarthrosis Due to Enoxaparin Therapy Ann. Pharmacother., November 1, 2006; 40(11): 2074 - 2074. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Ickx and A. Steib Perioperative management of patients receiving vitamin K antagonists: [Prise en charge perioperatoire des patients traites aux antagonistes de la vitamine K] Can J Anesth, June 1, 2006; 53(6_suppl): S113 - S122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kulik, F. D. Rubens, P. S. Wells, C. Kearon, T. G. Mesana, J. van Berkom, and B.-K. Lam Early Postoperative Anticoagulation After Mechanical Valve Replacement: A Systematic Review Ann. Thorac. Surg., February 1, 2006; 81(2): 770 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Goldhaber "Bridging" and Mechanical Heart Valves: Perils, Promises, and Predictions Circulation, January 31, 2006; 113(4): 470 - 472. [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Butchart, C. Gohlke-Barwolf, M. J. Antunes, P. Tornos, R. De Caterina, B. Cormier, B. Prendergast, B. Iung, H. Bjornstad, C. Leport, et al. Recommendations for the management of patients after heart valve surgery Eur. Heart J., November 2, 2005; 26(22): 2463 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Spyropoulos, F. J. Frost, J. S. Hurley, and M. Roberts Costs and Clinical Outcomes Associated With Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Bridging in Patients Receiving Long-term Oral Anticoagulant Therapy Chest, May 1, 2004; 125(5): 1642 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Elkayam, H. Singh, A. Irani, and M. W. Akhter Anticoagulation in Pregnant Women With Prosthetic Heart Valves Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 107 - 115. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF]
|
|
|
|
|
|
I Ferreira, L Dos, P Tornos, I Nicolau, G Permanyer-Miralda, and J Soler-Soler Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol Heart, May 1, 2003; 89(5): 527 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Ansell The Perioperative Management of Warfarin Therapy Arch Intern Med, April 28, 2003; 163(8): 881 - 883. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Collet, G. Montalescot, E. Fine, J.-L. Golmard, M. Dalby, R.e. Choussat, A. Ankri, R. Dumaine, C. Lesty, N. Vignolles, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials J. Am. Coll. Cardiol., January 1, 2003; 41(1): 8 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Schafer, M. N. Levine, B. A. Konkle, and C. Kearon Thrombotic Disorders: Diagnosis and Treatment Hematology, January 1, 2003; 2003(1): 520 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahm, G. Hafner, H. Schinzel, E. Mayer, D. Prufer, and H. Oelert Early antithrombotic management after valve replacement Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q12 - Q15. [Abstract] [PDF]
|
|
|
|
|
|
M. Perleth and R. Busse Health technology assessment of oral anticoagulation following heart valve replacement Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q60 - Q64. [Abstract] [PDF]
|
|
|
|
|
|
G. HANANIA Management of anticoagulants during pregnancy Heart, August 1, 2001; 86(2): 125 - 126. [Full Text] [PDF]
|
|
|
|
|
|
J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov, and D. Thomas Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris Circulation, February 6, 2001; 103(5): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gohlke-Bärwolf VALVE DISEASE: Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery Heart, November 1, 2000; 84(5): 567 - 572. [Full Text]
|
|